Exclusive AI analysis by The Herald Sun has revealed the common questions, mistakes, themes and topics of the five most ...
(Head of Commercial: Mike Petroutsas, "Astellas") today announced final overall survival (OS) results from the Phase 3 EMBARK study evaluating XTANDI ® (enzalutamide), in combination with leuprolide ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback